Pharmacogenomics of Antidepressant Treatment Outcomes

Pharmacogenomics examines how inherited genetic variation affects individual responses to antidepressant medications, aiming to move beyond the traditional trial-and-error approach. Key drug-metabolising enzymes such as CYP2D6 and CYP2C19 show common genetic polymorphisms that influence blood levels and adverse-effect profiles of selective serotonin reuptake inhibitors, tricyclics and novel agents. Beyond single genes, genome-wide studies reveal a polygenic architecture in which dozens or hundreds of variants each contribute modestly to treatment efficacy and tolerability. Emerging approaches combine genetic markers with clinical features—such as age, baseline symptom severity and comorbidities—to enhance prediction of response and remission. Multi-omics integration and advanced computational methods are refining biomarker discovery, with the ultimate goal of personalised prescribing that improves remission rates, reduces side-effects and shortens the time to effective treatment across diverse populations.

Research from Nature Portfolio

Foundational work has demonstrated the feasibility of drug-specific prediction models that integrate genetic and clinical variables. In one study, elastic net logistic models were trained on a combination of common genetic variants and baseline clinical measures to predict remission with either escitalopram or nortriptyline. The escitalopram model, incorporating eleven genetic markers and six clinical factors, achieved an area under the receiver operating characteristic curve (AUC) of 0.77 in an independent validation cohort, accounting for approximately 30% of variance in remission. A separate model using twenty genetic variants predicted nortriptyline remission with a similar AUC of 0.77, explaining around 36% of variance. These drug-specific predictive frameworks underscore the potential of multivariable pharmacogenomic profiling to guide antidepressant selection.

Pharmacogenomics of Antidepressant Treatment Outcomes publication trend

The graph below shows the total number of articles in pharmacogenomics of antidepressant treatment outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Pharmacogenomics: the study of how genetic variation influences individual responses to medications.

Single nucleotide polymorphism (SNP): a variation at a single base position in the genome among individuals.

Genome-wide association study (GWAS): an observational study scanning the genome for genetic variants associated with a trait or outcome.

Genetic risk score (GRS): a composite measure of genetic predisposition calculated from multiple risk-associated variants.

Machine learning: computational methods that identify patterns in data to make predictions or decisions without explicit programming of rules.

Area under the receiver operating characteristic curve (AUROC): a performance metric for classifiers, indicating their ability to distinguish between outcome classes.

References

1. AI-assisted prediction of differential response to antidepressant classes using electronic health records. npj Digital Medicine (2023).
2. A genetic risk score to predict treatment nonresponse in psychotic depression. Translational Psychiatry (2024).
3. Antidepressant drug-specific prediction of depression treatment outcomes from genetic and clinical variables. Scientific Reports (2018).